The Creso Pharma (ASX:CPH) share price jumped 6% today. Here's why

Investors responded well to the healthcare company's step forward today…

a man sits on his sofa loong at his phone and raises a fist to the air in happy celebration.

Image source: Getty Images

Key points

  • The Creso Pharma share price shot out the blocks this morning before ending the day 6% higher
  • It has acquired a US-based company manufacturing both CBD and non-CBD products
  • The Creso Pharma share price has fallen 57% in 12 months

The Creso Pharma Ltd (ASX: CPH) share price soared today after the company announced it was to enter the US market.

The cannabis-focused healthcare company revealed it is to acquire Colorado-based consumer packaged goods company Sierra Sage Herbs, LLC.

The Creso Pharma share price jumped 16% to 9.9 cents in early trade before settling back to 9 cents, a 5.88% gain on yesterday's close.

So what does this acquisition mean for investors?

Let's read on…

What fuelled the Creso Pharma share price?

The Creso Pharma share price spiked on today's announcement. The company is now positioned to enter the US market through the acquisition of the already-established US-based business, Sierra Sage Herbs — and more so, the Green Goo brand.

Its product portfolio includes beauty and personal care, first aid, sexual wellness products (non-CBD) and CBD products. The range already has 90,000 points of sale, and a large direct-to-consumer base both in and out of the US.

Creso Pharma believes the US CBD market to be "large and quickly growing", and estimates it will hit US$12 billion by 2026.

The company will acquire SSH for an up-front purchase price of US$21 million (with additional future payments based on estimated revenue targets of US$10 million in CY 2022 and up to US$20 million in CY 2023).

Creso Pharma aims to leverage and grow the existing Green Goo customer base and to introduce them to its own range of products — including therapeutics, nutraceuticals, topicals, and animal feed.

Comment from management

Speaking on the news driving the Creso Pharma share price today, group CEO and managing director William Lay said:

The acquisition of Sierra Sage Herbs and the company's product range is a major milestone for Creso Pharma. It marks entry into the US CBD market and provides a strong foundation to rapidly scale up operations, product development and sales, as well as further M&A transactions.

Creso Pharma is expected to benefit from SSH's existing revenue streams. We expect SSH's product sales to continue growing significantly in coming years, and the transaction implies material accretion on several metrics for Creso Pharma. Coupled with our existing sales channels, we have the potential to significantly grow our earnings profile in the near term.

Sierra Sage Herbs CEO and co-founder Jodi Scott said:

We started this company because we knew that plant-based alternatives could do more. We combined our passions for science, wellness, herbology and wound care into a line of safe, effective all natural products and so began our journey to change first aid as we know it.

That seed has become one of the most disruptive CPG brands in personal care — and this is just the beginning.

Creso Pharma share price snapshot

Over the last 12 months, the Creso Pharma share price has dropped by 57%. However, it is up nearly 10% this year to date.

The company has a market capitalisation of $104.40 million and 1.23 billion shares issued.

Motley Fool contributor Alice de Bruin has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »